380 related articles for article (PubMed ID: 28323503)
1. Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Jensterle M; Goricar K; Janez A
Endocr Res; 2017 Nov; 42(4):261-268. PubMed ID: 28323503
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
3. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.
Van Raalte DH; van Genugten RE; Eliasson B; Möller-Goede DL; Mari A; Tura A; Wilson C; Fleck P; Taskinen MR; Smith U; Diamant M
Eur J Endocrinol; 2014 Apr; 170(4):565-74. PubMed ID: 24421302
[TBL] [Abstract][Full Text] [Related]
4. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Eliasson B; Möller-Goede D; Eeg-Olofsson K; Wilson C; Cederholm J; Fleck P; Diamant M; Taskinen MR; Smith U
Diabetologia; 2012 Apr; 55(4):915-25. PubMed ID: 22237690
[TBL] [Abstract][Full Text] [Related]
5. DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.
Ferjan S; Janez A; Jensterle M
Endocr Pract; 2018 Jan; 24(1):69-77. PubMed ID: 29144805
[TBL] [Abstract][Full Text] [Related]
6. Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
Kawashima S; Matsuoka TA; Kaneto H; Tochino Y; Kato K; Yamamoto K; Yamamoto T; Matsuhisa M; Shimomura I
Biochem Biophys Res Commun; 2011 Jan; 404(1):534-40. PubMed ID: 21144823
[TBL] [Abstract][Full Text] [Related]
7. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
[TBL] [Abstract][Full Text] [Related]
8. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index.
Aoki C; Suzuki K; Kuroda H; Sagara M; Shimizu M; Kasai K; Aso Y
Nagoya J Med Sci; 2017 Feb; 79(1):9-16. PubMed ID: 28303056
[TBL] [Abstract][Full Text] [Related]
9. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Bosi E; Ellis GC; Wilson CA; Fleck PR
Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
[TBL] [Abstract][Full Text] [Related]
11. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
Elkind-Hirsch KE; Paterson MS; Seidemann EL; Gutowski HC
Fertil Steril; 2017 Jan; 107(1):253-260.e1. PubMed ID: 28228317
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Triplitt C; Cersosimo E; DeFronzo RA
Vasc Health Risk Manag; 2010 Sep; 6():671-90. PubMed ID: 20859539
[TBL] [Abstract][Full Text] [Related]
13. Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer.
Hu L; Shen H; Wu QF; Tian L; Hu MH
Clin Exp Obstet Gynecol; 2014; 41(3):288-92. PubMed ID: 24992778
[TBL] [Abstract][Full Text] [Related]
14. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.
Glintborg D; Hermann AP; Andersen M; Hagen C; Beck-Nielsen H; Veldhuis JD; Henriksen JE
Fertil Steril; 2006 Aug; 86(2):385-97. PubMed ID: 16782094
[TBL] [Abstract][Full Text] [Related]
15. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Ndefo UA; Okoli O; Erowele G
Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
[TBL] [Abstract][Full Text] [Related]
16. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
17. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.
Kashani L; Omidvar T; Farazmand B; Modabbernia A; Ramzanzadeh F; Tehraninejad ES; Ashrafi M; Tabrizi M; Akhondzadeh S
Psychoneuroendocrinology; 2013 Jun; 38(6):767-76. PubMed ID: 22999261
[TBL] [Abstract][Full Text] [Related]
18. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Cho LW; Kilpatrick ES; Keevil BG; Coady AM; Atkin SL
Clin Endocrinol (Oxf); 2009 Feb; 70(2):233-7. PubMed ID: 18547343
[TBL] [Abstract][Full Text] [Related]
19. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
[TBL] [Abstract][Full Text] [Related]
20. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
